Plain-English translation of NCT07323641 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing combined with for people with advanced lung cancer that has stopped responding to alone. is a medication that targets a specific genetic mutation in lung cancer cells, but sometimes cancer finds ways to resist it. Researchers believe adding this new medication might help overcome that resistance.
Some lung cancers develop resistance to even though they have the mutation the drug is designed to target. This trial is exploring whether combining the medication with a new treatment approach can help people whose cancer is growing despite continuing their current therapy.
You likely qualify if…
You likely don't qualify if…
You will receive two medications: the new drug intravenously (through an IV) twice in the first three months, then once per month; and a daily oral pill you take at home. You'll visit the clinic regularly for blood tests, CT scans, and sometimes brain imaging to monitor how your cancer is responding. The entire treatment continues for as long as your cancer isn't growing and you're tolerating the medications well, with follow-up visits for up to 2 years after treatment ends.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States